Skip to main content
ClaudeWave
Skill1.4k repo starsupdated today

tooluniverse-clinical-trial-matching

This Claude Code skill matches patients to clinical trials by analyzing their molecular profiles, including specific mutations and biomarkers, then searches ClinicalTrials.gov and cross-references databases like CIViC, OpenTargets, and ChEMBL to generate ranked trial recommendations with evidence grades and eligibility scores. Use it when patients need precision-oncology trial matching based on genotype, biomarker-driven selection, or when evaluating trial eligibility for cancer or rare-disease care.

Install in Claude Code
Copy
git clone --depth 1 https://github.com/mims-harvard/ToolUniverse /tmp/tooluniverse-clinical-trial-matching && cp -r /tmp/tooluniverse-clinical-trial-matching/plugin/skills/tooluniverse-clinical-trial-matching ~/.claude/skills/tooluniverse-clinical-trial-matching
Then start a new Claude Code session; the skill loads automatically.

SKILL.md

# Clinical Trial Matching for Precision Medicine

Transform patient molecular profiles and clinical characteristics into prioritized clinical trial recommendations. Searches ClinicalTrials.gov and cross-references with molecular databases (CIViC, OpenTargets, ChEMBL, FDA) to produce evidence-graded, scored trial matches.

**KEY PRINCIPLES**:
1. **Report-first approach** - Create report file FIRST, then populate progressively
2. **Patient-centric** - Every recommendation considers the individual patient's profile
3. **Molecular-first matching** - Prioritize trials targeting patient's specific biomarkers

## Molecular Matching Priority

Match patients to trials by molecular profile FIRST (specific mutations), then by disease stage, then by prior treatments. A patient with EGFR L858R should match to EGFR-targeted trials regardless of other factors.
4. **Evidence-graded** - Every recommendation has an evidence tier (T1-T4)
5. **Quantitative scoring** - Trial Match Score (0-100) for every trial
6. **Eligibility-aware** - Parse and evaluate inclusion/exclusion criteria
7. **Actionable output** - Clear next steps, contact info, enrollment status
8. **Source-referenced** - Every statement cites the tool/database source
9. **Completeness checklist** - Mandatory section showing analysis coverage
10. **English-first queries** - Always use English terms in tool calls. Respond in user's language

## LOOK UP, DON'T GUESS
When uncertain about any scientific fact, SEARCH databases first rather than reasoning from memory. A database-verified answer is always more reliable than a guess.

---

## COMPUTE, DON'T DESCRIBE
When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.

## When to Use

Apply when user asks:
- "What clinical trials are available for my NSCLC with EGFR L858R?"
- "Patient has BRAF V600E melanoma, failed ipilimumab - what trials?"
- "Find basket trials for NTRK fusion"
- "Breast cancer with HER2 amplification, post-CDK4/6 inhibitor trials"
- "KRAS G12C colorectal cancer clinical trials"
- "Immunotherapy trials for TMB-high solid tumors"
- "Clinical trials near Boston for lung cancer"
- "What are my options after failing osimertinib for EGFR+ NSCLC?"

**NOT for** (use other skills instead):
- Single variant interpretation without trial focus -> Use `tooluniverse-cancer-variant-interpretation`
- Drug safety profiling -> Use `tooluniverse-adverse-event-detection`
- Target validation -> Use `tooluniverse-drug-target-validation`
- General disease research -> Use `tooluniverse-disease-research`

---

## Input Parsing

### Required Input
- **Disease/cancer type**: Free-text disease name (e.g., "non-small cell lung cancer", "melanoma")

### Strongly Recommended
- **Molecular alterations**: One or more biomarkers (e.g., "EGFR L858R", "KRAS G12C", "PD-L1 50%", "TMB-high")
- **Stage/grade**: Disease stage (e.g., "Stage IV", "metastatic", "locally advanced")
- **Prior treatments**: Previous therapies and outcomes (e.g., "failed platinum chemotherapy", "progressed on osimertinib")

### Optional
- **Performance status**: ECOG or Karnofsky score
- **Geographic location**: City/state for proximity filtering
- **Trial phase preference**: I, II, III, IV, or "any"
- **Intervention type**: drug, biological, device, etc.
- **Recruiting status preference**: recruiting, not yet recruiting, active

For biomarker parsing rules and gene symbol normalization, see [MATCHING_ALGORITHMS.md](./MATCHING_ALGORITHMS.md).

---

## Workflow Overview

```
Input: Patient profile (disease + biomarkers + stage + prior treatments)

Phase 1: Patient Profile Standardization
  - Resolve disease to EFO/ontology IDs (OpenTargets, OLS)
  - Parse molecular alterations to gene + variant
  - Resolve gene symbols to Ensembl/Entrez IDs (MyGene)
  - Classify biomarker actionability (FDA-approved vs investigational)

Phase 2: Broad Trial Discovery
  - Disease-based trial search (ClinicalTrials.gov)
  - Biomarker-specific trial search
  - Intervention-based search (for known drugs targeting patient's biomarkers)
  - Deduplicate and collect NCT IDs

Phase 3: Trial Characterization (batch, groups of 10)
  - Eligibility criteria, conditions/interventions, locations, status, descriptions

Phase 4: Molecular Eligibility Matching
  - Parse eligibility text for biomarker requirements
  - Match patient's molecular profile to trial requirements
  - Score molecular eligibility (0-40 points)

Phase 5: Drug-Biomarker Alignment
  - Identify trial intervention drugs and mechanisms (OpenTargets, ChEMBL)
  - FDA approval status for biomarker-drug combinations
  - Classify drugs (targeted therapy, immunotherapy, chemotherapy)

Phase 6: Evidence Assessment
  - FDA-approved biomarker-drug combinations
  - Clinical trial results (PubMed), CIViC evidence, PharmGKB
  - Evidence tier classification (T1-T4)

Phase 7: Geographic & Feasibility Analysis
  - Trial site locations, enrollment status, proximity scoring

Phase 8: Alternative Options
  - Basket trials, expanded access, related studies

Phase 9: Scoring & Ranking (0-100 composite score)
  - Tier classification: Optimal (80-100) / Good (60-79) / Possible (40-59) / Exploratory (0-39)

Phase 10: Report Synthesis
  - Executive summary, ranked trial list, evidence grading, completeness checklist
```

---

## Critical Tool Parameters

### Clinical Trial Search Tools

| Tool | Key Parameters | Notes |
|------|---------------|-------|
| `search_clinical_trials` | `query_term` (REQ), `condition`, `intervention`, `pageSize` | Main search (ClinicalTrials.gov, U.S./global) |
| `search_clinical_trials` | `action="search_studies"` (REQ), `condition`, `intervention`, `limit` | Alternative search |
| `get_clinical_trial_descriptions` | `action="get_study_details"` (REQ), `nct_id
setup-tooluniverseSkill

Install and configure ToolUniverse for any use case — MCP server (chat-based), CLI (command line with 9 subcommands), or Python SDK (Coding API with 3 calling patterns). Covers uv/uvx setup, MCP configuration for 12+ AI clients (Cursor, Claude Desktop, Windsurf, VS Code, Codex, Gemini CLI, Trae, Cline, etc.), full CLI reference (tu list/grep/find/info/run/test/status/build/serve), Coding API quickstart, agentic tools, code executor, API key walkthrough, skill installation, and upgrading. Use when user asks how to set up ToolUniverse, which access mode to use (MCP vs CLI vs SDK), configuring MCP servers, using the CLI, troubleshooting installation, upgrading, or mentions installing ToolUniverse or setting up scientific tools. Also triggers for "how do I use ToolUniverse", "what's the best way to access tools", "command line", "tu command", "coding API", "tu build".

tooluniverse-acmg-variant-classificationSkill

Systematic ACMG/AMP germline variant classification with all 28 criteria (PVS1, PS1-4, PM1-6, PP1-5, BA1, BS1-4, BP1-7) for clinical significance. Produces 5-tier verdict (Pathogenic / Likely Pathogenic / VUS / Likely Benign / Benign) with cited evidence per criterion. Use for variant interpretation, VUS resolution, and pathogenicity assessment. Combines ClinVar, gnomAD, computational predictors, and gene-mechanism context.

tooluniverse-admet-predictionSkill

Comprehensive ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiling for drug candidates. Integrates ADMET-AI predictions, SwissADME drug-likeness, PubChemTox experimental toxicity, ChEMBL clinical data, Lipinski rule-of-five, and CYP interaction data. Use for drug-likeness assessment, BBB penetration, bioavailability, hepatotoxicity prediction, ADME/PK profiling, or screening compound libraries before lab testing.

tooluniverse-adverse-event-detectionSkill

Detect and analyze adverse drug event signals using FDA FAERS reports, drug labels, and disproportionality statistics (PRR, ROR, IC). Generates quantitative safety signal scores (0-100) with evidence grading. Use for post-market surveillance, pharmacovigilance, drug safety assessment, regulatory submissions, and detecting rare AE signals not visible in clinical trials.

tooluniverse-adverse-outcome-pathwaySkill

Map environmental and industrial chemicals to adverse outcome pathways (AOPs) — molecular initiating event to organ-level toxicity. Uses AOPWiki, GHS classification, IARC carcinogen status, and LD50 data. Use for environmental/industrial chemical risk assessment, regulatory-grade hazard characterization, and AOP stressor mapping. Distinct from drug-safety analysis (use tooluniverse-pharmacovigilance for drugs).

tooluniverse-aging-senescenceSkill

Aging biology, cellular senescence, and longevity research. Covers senescence markers (p16/CDKN2A, SASP, SA-beta-gal), aging hallmarks, senolytic drug discovery (dasatinib+quercetin, fisetin, navitoclax), epigenetic clocks, telomere biology, and longevity GWAS. Use for senescence-pathway analysis, age-related disease genetics, senolytic-target discovery, and centenarian-genetics queries. Distinguishes correlative vs causal evidence (knockout, intervention).

tooluniverse-antibody-engineeringSkill

Therapeutic antibody engineering and optimization, lead-to-clinical-candidate. Covers sequence humanization (germline alignment, framework retention), affinity maturation, developability (aggregation, stability, PTMs), structure modeling (AlphaFold/PDB CDR analysis), immunogenicity prediction, and manufacturing feasibility. Use for biologic-drug optimization, mAb design review, biosimilar engineering, and clinical-precedent comparison.

tooluniverse-binder-discoverySkill

Discover novel small-molecule binders for protein targets using structure-based and ligand-based screening. Covers druggability assessment, known-ligand mining (ChEMBL, BindingDB), similarity expansion, ADMET filtering, and synthesis feasibility. Use for hit identification, virtual screening, target-to-compounds workflows, and lead-finding before commit-to-medchem.